At Astria, we are focused on the discovery, development, and commercialization of novel therapeutics. Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases.

Our lead program candidate, STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein that is in clinical development for the treatment of hereditary angioedema. We initiated a Phase 1a clinical trial in 2022, and anticipate preliminary results by year-end.

Astria TX on Facebook Astria TX on Twitter Astria TX on LinkedIn Astria TX on Instagram